Pillar Point Partners is a clinical-stage biotechnology company developing novel disease-modifying therapies for rare lysosomal storage diseases (LSDs), a group of inherited metabolic disorders affecting approximately 50,000 patients across major markets. The company's pipeline includes small molecule therapies (PLX-200, PLX-300, and a combination therapy PLX-100) and a preclinical gene therapy (PLX-400) targeting diseases such as neuronal ceroid lipofuscinoses, Krabbe disease, Sandhoff disease, and Niemann-Pick disease, most of which currently lack approved disease-modifying treatments. The company is pre-revenue and generates value through clinical development of its candidates, with plans to pursue regulatory approval via existing pathways and eventually commercialize through internal sales capabilities or strategic partnerships.